ESPAC-4: Adjuvant Gemcitabine/Capecitabine in Resected Pancreatic Cancer
The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.